The Contrast Media Wars Get Hot
Executive Summary
AmeriNet officials were upset that Mallinckrodt was unwilling to offer AmeriNet the same terms it had Premier. When Mallinckrodt said "no", AmeriNet turned to Bracco.
You may also be interested in...
Amersham's Push for High-Value Diagnostics
Amersham Health is applying Big Pharma marketing and R&D strategies to the traditionally stodgy, highly price-sensitive field of diagnostic imaging contrast agents. It has been far more aggressive than competitors in working to make innovation the basis of competition. But some analysts question whether the company can maintain near-to-mid-term growth as it awaits results of its risky, long-term effort in molecular imaging.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.